A machine learning-based approach for the inference of immunotherapy biomarker status in lung adenocarcinoma from hematoxylin and eosin (H&E) histopathology images.

3122 Background: The current standard work-up for both diagnosis and predictive biomarker testing in metastatic non-small cell lung cancer (NSCLC), can exhaust an entire tumor specimen. Notably, gene mutation panels or tumor mutation burden (TMB) testing currently requires 10 tissue slides and ranges from 10 days to 3 weeks from sample acquisition to test result. As more companion diagnostic (CDx)-restricted drugs are developed for NSCLC, rapid,...